Investing.com-- Most Asian stocks advanced on Thursday with technology shares tracking gains in Nvidia, which recently crossed a $4 trillion valuation, although concerns over U.S.

Investing.com-- Oil prices steadied near two-week highs in Asian trading on Thursday as investors assessed new trade tariff ...

Gains in Nvidia helped the NASDAQ Composite finish at a record-high close of 20,611.34 points. The S&P 500 rose 0.6% to 6,263 ...

Lula said that Brazil will respond with the Law of Economic Reciprocity– a legal framework enacted in 2025 that allows the country to respond proportionately to unilateral trade, investment, or ...

Investing.com -- Britain and France have agreed to order more Storm Shadow cruise missiles and accelerate work on developing a replacement system as part of a refreshed defense agreement.

AWS developed its custom-built infrastructure solution—the In-Row Heat Exchanger (IRHX)—instead of adopting widespread industry-standard liquid cooling solutions. This approach allows AWS to ...

Investing.com -- Fitch Ratings has downgraded Polaris (NYSE: PII) Inc.’s Long-Term Issuer Default Rating and senior unsecured notes rating to ’BBB-’ from ’BBB’, with a Negative outlook.

For fiscal year 2026, AZZ provided guidance of $5.75-$6.25 for adjusted EPS, compared to the analyst consensus of $5.88. The company expects revenue between $1.63-1.73 billion, in line with the ...

A Meta Platforms (NASDAQ: META) research scientist has delivered a harsh critique of the company’s artificial intelligence ...

Investing.com -- AGCO Corporation (NYSE: AGCO) stock rose 2.7% after the agricultural machinery manufacturer announced a new $1 billion share repurchase program.

Investing.com -- Nurix Therapeutics Inc (NASDAQ: NRIX) reported better-than-expected financial results for its fiscal second quarter ended May 31, 2025, driven by significant milestone payments from ...

Investing.com -- Ultragenyx Pharmaceutical (TADAWUL: 2070) Inc. (NASDAQ: RARE) stock plummeted 33% after the company announced its Phase 3 Orbit study for UX143 (setrusumab) in osteogenesis imperfecta ...